Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

First Posted Date
2024-03-15
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1200
Registration Number
NCT06312176
Locations
🇩🇰

Vejle Sygehus ( Site 1183), Vejle, Syddanmark, Denmark

🇳🇱

Isala, locatie Zwolle ( Site 1525), Zwolle, Overijssel, Netherlands

🇵🇹

Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1661), Lisbon, Lisboa, Portugal

and more 143 locations

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

First Posted Date
2024-03-15
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
780
Registration Number
NCT06312137
Locations
🇨🇳

Zhongshan Hospital of Fudan University ( Site 1325), Shangai, Shanghai, China

🇫🇷

Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, France

🇫🇷

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, France

and more 124 locations

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

First Posted Date
2024-03-12
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
488
Registration Number
NCT06304974
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Qiu Guoqin
Target Recruit Count
30
Registration Number
NCT06303583
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Myeloprotection With Trilaciclib in Pan-cancer Population

First Posted Date
2024-03-07
Last Posted Date
2024-03-07
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
132
Registration Number
NCT06297811
Locations
🇨🇳

Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

First Posted Date
2024-02-28
Last Posted Date
2024-06-26
Lead Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Target Recruit Count
524
Registration Number
NCT06279364
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

First Posted Date
2024-02-09
Last Posted Date
2024-11-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
37
Registration Number
NCT06251973
Locations
🇺🇸

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

First Posted Date
2024-02-07
Last Posted Date
2024-05-08
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
30
Registration Number
NCT06245889
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

First Posted Date
2024-02-07
Last Posted Date
2024-11-21
Lead Sponsor
Eikon Therapeutics
Target Recruit Count
70
Registration Number
NCT06246110
Locations
🇺🇸

Tennessee Cancer Specialists, Knoxville, Tennessee, United States

🇺🇸

Southern Cancer Care, Daphne, Alabama, United States

🇺🇸

Ironwood Cancer and Research Center, Chandler, Arizona, United States

and more 31 locations

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

First Posted Date
2024-02-05
Last Posted Date
2024-04-02
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
48
Registration Number
NCT06241235
Locations
🇨🇳

Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy